title: Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
abstract: BACKGROUND
  The combination of Carboplatin and Paclitaxel is considered the standard of care as initial chemotherapy for Advanced Ovarian Cancer (AOC). We compared this regimen with the combination of Cisplatin, Paclitaxel and Doxorubicin.
  
  
  METHODS
  Patients with AOC were randomised to either six courses of Paclitaxel 175mg/m(2) plus Carboplatin 7AUC or Paclitaxel at the same dose plus Cisplatin 75mg/m(2) plus Doxorubicin 40mg/m(2).
  
  
  RESULTS
  Analysis was performed on 451 patients. The treatment groups were well balanced with regard to patient and disease characteristics. Performance status (PS) was better in the anthracycline arm. In terms of severe toxicity, the only significant difference between the two groups was the development of febrile neutropaenia in the anthracycline arm. Overall response rate was similar in both groups. With a median follow-up of 57.5 months, a marginal significance towards improved Progression-Free Survival (PFS) was noted in favour of the anthracycline arm, whilst there was no difference in overall survival. In multivariate analysis the hazard of disease progression at any time was significantly decreased by 25.5% for patients of the anthracycline arm.
  
  
  CONCLUSIONS
  The combination of Cisplatin, Paclitaxel and Doxorubicin demonstrates a marginal PFS improvement, but no additional survival benefit when compared with the standard Carboplatin/Paclitaxel regimen.
authors.affiliation: Agii Anargiri Cancer Hospital, Hellenic Cooperative Oncology Group, Hatzikonstanti 18,115 24 Athens, Greece. hecogaga@otenet.gr
authors.forename: Gerasimos
authors.initials: G
authors.lastname: Aravantinos
authors.forename: George
authors.initials: G
authors.lastname: Fountzilas
authors.forename: Aristotelis
authors.initials: A
authors.lastname: Bamias
authors.forename: Irene
authors.initials: I
authors.lastname: Grimani
authors.forename: Spyridon
authors.initials: S
authors.lastname: Rizos
authors.forename: Haralabos P
authors.initials: HP
authors.lastname: Kalofonos
authors.forename: Dimosthenis V
authors.initials: DV
authors.lastname: Skarlos
authors.forename: Theofanis
authors.initials: T
authors.lastname: Economopoulos
authors.forename: Paris A
authors.initials: PA
authors.lastname: Kosmidis
authors.forename: George P
authors.initials: GP
authors.lastname: Stathopoulos
authors.forename: Evangelos
authors.initials: E
authors.lastname: Briasoulis
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Pectasides
authors.forename: Epaminondas
authors.initials: E
authors.lastname: Samantas
authors.forename: Eleni
authors.initials: E
authors.lastname: Timotheadou
authors.forename: Christos
authors.initials: C
authors.lastname: Papadimitriou
authors.forename: Alexandros
authors.initials: A
authors.lastname: Papanikolaou
authors.forename: Adimchi
authors.initials: A
authors.lastname: Onyenadum
authors.forename: Pavlos
authors.initials: P
authors.lastname: Papakostas
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Bafaloukos
authors.forename: Meletios A
authors.initials: MA
authors.lastname: Dimopoulos
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D010349:Patient Compliance; D016896:Treatment Outcome
chemical_list: D004317:Doxorubicin; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin